Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII
Kyowa Kirin’s NHE3 inhibitor tenapanor (KHK7791) hit its primary target, a decrease in the total number of pills from baseline, in a PII study in Japan in patients with hyperphosphatemia on hemodialysis, the company said on June 8. The primary…
To read the full story
Related Article
- Tenapanor Hits Mark in Japan Hyperphosphatemia Study: Kyowa Kirin
December 14, 2021
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
BUSINESS
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…